Are regimens containing rituximab effective in the initial treatment of Epstein-Barr virus-positive natural killer cell lymphoproliferative disease-associated hemophagocytic lymphohistiocytosis?

International Journal of Hematology

Volumn 98, Issue 3, 2013, Pages 375-377

  Imashuku, Shinsaku ^a   Kudo, Naoko ^a   Kubo, Kagekatsu ^a   Yachie, Akihiro ^b  

^a Takasago seibu Hospital   (Japan)

^b KANAZAWA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; ETOPOSIDE; FRESH FROZEN PLASMA; GABEXATE MESILATE; PREDNISOLONE; RITUXIMAB;

ADULT; B LYMPHOCYTE; CASE REPORT; COLLAGEN DISEASE; DISEASE COURSE; DRUG EFFICACY; EPSTEIN BARR VIRUS INFECTION; HEMOPHAGOCYTIC SYNDROME; HUMAN; INFECTION; INFLUENZA A; LETTER; LYMPHOPROLIFERATIVE DISEASE; MALE; NATURAL KILLER CELL; T LYMPHOCYTE; TREATMENT DURATION; VIRUS PARTICLE;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; CYCLOSPORINE; DRUG THERAPY, COMBINATION; ETOPOSIDE; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOSUPPRESSIVE AGENTS; KILLER CELLS, NATURAL; LYMPHOHISTIOCYTOSIS, HEMOPHAGOCYTIC; LYMPHOPROLIFERATIVE DISORDERS; MALE; MIDDLE AGED; PREDNISOLONE; TIME FACTORS;

EID: 84884672192     PISSN: 09255710     EISSN: 18653774     Source Type: Journal    
DOI: 10.1007/s12185-013-1419-4     Document Type: Letter

References (8)

1. Imashuku S. Treatment of Epstein-Barr virus-related hemophagocytic lymphohistiocytosis (EBV-HLH); update 2010. J Pediatr Hematol Oncol. 2011;33:35-9.
2. Suzuki K, Ohshima K, Karube K, et al. Clinicopathological states of Epstein-Barr virus-associated T/NK-cell lymphoproliferative disorders (severe chronic active EBV infection) of children and young adults. Int J Oncol. 2004;24:1165-74.
3. Kimura H, Ito Y, Kawabe S, et al. EBV-associated T/NK-cell lymphoproliferative diseases in nonimmunocompromised hosts: prospective analysis of 108 cases. Blood. 2012;119:673-86.
4. Milone MC, Tsai DE, Hodinka RL, et al. Treatment of primary Epstein-Barr virus infection in patients with X-linked lymphoproliferative disease using B-cell-directed therapy. Blood. 2005;105:994-6.
5. Balamuth NJ, Nichols KE, Paessler M, et al. Use of rituximab in conjunction with immunosuppressive chemotherapy as a novel therapy for Epstein Barr virus-associated hemophagocytic lymphohistiocytosis. J Pediatr Hematol Oncol. 2007;29:569-73.
6. Beutel K, Gross-Wieltsch U, Wiesel T, et al. Infection of T-lymphocytes in Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in children of non-Asian origin. Pediatr Blood Cancer. 2009;53:184-90.
7. Chellapandian D, Das R, Zelley K, et al. Use of the B-cell targeting antibody rituximab in the treatment of Epstein Barr virus-induced hemophagocytic lymphohistiocytosis. Br J Haematol. 2013;162:376-82.
8. Imashuku S, Hibi S, Tabata Y, et al. Outcome of clonal hemophagocytic lymphohistiocytosis: analysis of 32 cases. Leuk Lymphoma. 2000;37(5-6):577-84.